Get the Stockscreener App
55.89
3.18%
1.72
Moonlake Immunotherapeutics stock is traded at $55.89, with a volume of 253.81K.
It is up +3.18% in the last 24 hours and up +4.33% over the past month.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
See More
Previous Close:
$54.17
Open:
$54.6
24h Volume:
253.81K
Relative Volume:
0.50
Market Cap:
$3.55B
Revenue:
-
Net Income/Loss:
$-145.21M
P/E Ratio:
-24.30
EPS:
-2.3
Net Cash Flow:
$-140.12M
1W Performance:
+2.76%
1M Performance:
+4.33%
6M Performance:
+32.03%
1Y Performance:
+15.02%
1-Day Range:
$53.64
$56.13
1-Week Range:
$52.02
$56.13
52-Week Range:
$31.42
$58.26
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
Name
Moonlake Immunotherapeutics
Sector
Industry
Phone
41 41 510 8022
Address
DORFSTRASSE 29, ZUG
Compare MLTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
55.89 | 3.41B | 0 | -145.21M | -140.12M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-28-25 | Initiated | Rothschild & Co Redburn | Neutral |
| May-19-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Mar-18-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-17-25 | Upgrade | Goldman | Neutral → Buy |
| Nov-05-24 | Resumed | Wedbush | Outperform |
| Aug-26-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Apr-02-24 | Initiated | Goldman | Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Citigroup | Buy |
| Nov-02-23 | Initiated | Stifel | Buy |
| Sep-14-23 | Downgrade | Bryan Garnier | Buy → Neutral |
| Aug-31-23 | Initiated | Needham | Buy |
| Jun-15-23 | Initiated | Barclays | Equal Weight |
| May-01-23 | Initiated | Guggenheim | Buy |
| Mar-22-23 | Initiated | Wedbush | Outperform |
| Mar-09-23 | Initiated | BTIG Research | Buy |
| Feb-14-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-02-23 | Initiated | Bryan Garnier | Buy |
| Nov-11-22 | Initiated | Jefferies | Buy |
| Aug-25-22 | Initiated | SVB Leerink | Outperform |
| Jul-21-22 | Initiated | H.C. Wainwright | Buy |
| Jul-07-22 | Initiated | Cowen | Outperform |
View All
Moonlake Immunotherapeutics Stock (MLTX) Latest News
MoonLake Immunotherapeutics Shows Early Signs of Technical StrengthJuly 2025 Drop Watch & AI Enhanced Market Trend Forecasts - beatles.ru
Does MoonLake Immunotherapeutics have pricing powerWall Street Watch & High Accuracy Trade Signal Alerts - thegnnews.com
I'm Over the Moon About This Promising Biotech - TheStreet Pro
Ranking MoonLake Immunotherapeutics among high performing stocks via toolsPrice Action & AI Driven Stock Movement Reports - Newser
Real time social sentiment graph for MoonLake ImmunotherapeuticsInsider Buying & Stock Portfolio Risk Control - Newser
MoonLake Immunotherapeutics: A High-Conviction Speculative Play on Sonelokimab's Transformative Potential - AInvest
MoonLake Immunotherapeutics (MLTX): A Bull Case Theory - MSN
What data driven models say about MoonLake Immunotherapeutics’s futureQuarterly Risk Review & Daily Risk Controlled Trade Plans - Newser
When is the best time to exit MoonLake ImmunotherapeuticsJuly 2025 Fed Impact & Growth Focused Entry Point Reports - Newser
MoonLake Immunotherapeutics stock trend outlook and recovery path2025 Volatility Report & Safe Capital Growth Plans - Newser
MoonLake Immunotherapeutics Company’s Quarterly Earnings Growth: What the Numbers SayJuly 2025 Fed Impact & AI Powered Market Entry Strategies - Newser
Should you hold or exit MoonLake Immunotherapeutics now2025 Dividend Review & Daily Chart Pattern Signal Reports - Newser
Sector ETF performance correlation with MoonLake ImmunotherapeuticsLong Setup & Risk Controlled Daily Trade Plans - Newser
What recovery options are there for MoonLake Immunotherapeutics2025 Technical Patterns & Free Community Supported Trade Ideas - Newser
MoonLake Immunotherapeutics stock trend forecastWeekly Stock Recap & Weekly Return Optimization Alerts - Newser
Visual analytics tools that track MoonLake Immunotherapeutics performanceJuly 2025 Outlook & Short-Term High Return Ideas - Newser
Are MoonLake Immunotherapeutics' (MLTX) Rising Losses a Sign of Strategic Investment or Mounting Pressure? - simplywall.st
Real time social sentiment graph for MoonLake Immunotherapeutics [Trade Risk Assessment]Safe Entry Zone Identification - Newser
Using Python tools to backtest MoonLake Immunotherapeutics strategies [July 2025 Macro Moves]Real-Time Volume Analysis Alerts - Newser
MoonLake Immunotherapeutics: Maintaining A Small Holding (NASDAQ:MLTX) - Seeking Alpha
MoonLake Immunotherapeutics: Robust Financials and Promising Phase 3 VELA Program Back Strong Buy Rating - AInvest
MoonLake Immunotherapeutics: Strong Buy Rating Amid Promising Phase 3 VELA Program and Robust Financial Position - TipRanks
Does Rising Loss at MoonLake Immunotherapeutics (MLTX) Signal Strategic Investment or Expense Control Challenges? - simplywall.st
Rising Losses Might Change the Case for Investing in MoonLake Immunotherapeutics (MLTX) - simplywall.st
Wedbush Has Negative Forecast for MLTX Q3 Earnings - Defense World
Intraday Charts Show Spike in MoonLake Immunotherapeutics ActivitySwing Trade Entry With Volume Triggers Released - beatles.ru
Leerink Partners Maintains Buy Rating on MoonLake Immunotherapeutics with $73 Price Target - AInvest
Needham Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $66 - 富途牛牛
Goldman Sachs Boosts MoonLake Pharmaceuticals Target Price to $82, Maintains "Buy" Rating - AInvest
Clear Street Analyst Reiterates Buy Rating for MoonLake Immunotherapeutics with $108 Price Target - AInvest
MoonLake Bets Big On Its Nanobody Drug As Key Trials Approach - Finimize
MoonLake Immunotherapeutics Reports Q2 2025 Financials - TipRanks
Clear Street Initiates MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Announces Target Price $108 - 富途牛牛
MoonLake Immunotherapeutics reports Q2 EPS (87c), consensus (76c) - TipRanks
Guggenheim reiterates Buy rating on Moonlake Immunotherapeutics stock - Investing.com India
Guggenheim reiterates Buy rating on Moonlake Immunotherapeutics stock By Investing.com - Investing.com South Africa
MoonLake Immunotherapeutics: Buy Rating Driven by Promising SLK Phase 3 Data and Strong Financial Position - TipRanks
MoonLake Immunotherapeutics reports results for the quarter ended June 30Earnings Summary - TradingView
MoonLake Immunotherapeutics reports second quarter 2025 financial results and provides a business update - MarketScreener
MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results And Provides A Business Update - TradingView
MoonLake Immunotherapeutics Q2 Loss Widens - MarketScreener
MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update - Ariva
Earnings Flash (MLTX) MoonLake Immunotherapeutics Posts Q2 Net Loss $0.87 a Share, vs. FactSet Est of $0.68 Loss - MarketScreener
MoonLake Immunotherapeutics's Q2 net loss widens - MarketScreener
MoonLake Immunotherapeutics SEC 10-Q Report - TradingView
MoonLake Immunotherapeutics AG - Via Ritzau
How does MoonLake Immunotherapeutics compare to its industry peersDiscover stocks with explosive potential - Jammu Links News
Is it the right time to buy MoonLake Immunotherapeutics stockFree Consultation - Jammu Links News
What drives MoonLake Immunotherapeutics stock priceFree Stock Index Interpretation - Jammu Links News
How does MoonLake Immunotherapeutics generate profit in a changing economyDiscover top stock picks for aggressive growth - Jammu Links News
Is MoonLake Immunotherapeutics stock overvalued or undervaluedMaximize gains with professional stock picks - Jammu Links News
Moonlake Immunotherapeutics Stock (MLTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Moonlake Immunotherapeutics Stock (MLTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Moukheibir Catherine | Director |
Jul 03 '25 |
Sale |
48.79 |
23,500 |
1,146,565 |
0 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):